Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc News Story

$4.97 -0.5  -9.6%

Last Trade - 09/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £76.8m
Enterprise Value £11.9m
Revenue £n/a
Position in Universe 5145th / 6827

Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

Thu 19th November, 2020 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201119:nGNX95bxNR


BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq:
APRE), a biopharmaceutical company focused on developing and commercializing
novel cancer therapeutics that reactivate the mutant tumor suppressor protein,
p53, today announced that Christian S. Schade, Chairman and Chief Executive
Officer, and Eyal Attar, M.D., Chief Medical Officer, will participate in a
fireside chat at the virtual Piper Sandler Healthcare Conference being held
December 1-3, 2020.

The pre-recorded fireside chat will be accessible for a limited time beginning
November 23, 2020 in the Investors section of Aprea Therapeutics’ website at
www.aprea.com.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered
in Boston, Massachusetts with research facilities in Stockholm, Sweden,
focused on developing and commercializing novel cancer therapeutics that
reactivate mutant tumor suppressor protein, p53. The Company’s lead product
candidate is eprenetapopt (APR-246), a small molecule in clinical development
for hematologic malignancies, including myelodysplastic syndromes (MDS) and
acute myeloid leukemia (AML). Eprenetapopt has received Breakthrough Therapy,
Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug
designation from the European Commission for MDS, AML and ovarian cancer.
APR-548, a next generation small molecule reactivator of mutant p53, is being
developed for oral administration. For more information, please visit the
company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at
https://ir.aprea.com/ as a means of disclosing material nonpublic information
and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement
Certain information contained in this press release includes
“forward-looking statements”, within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, related to our clinical trials, regulatory
submissions and projected cash position. We may, in some cases use terms such
as “predicts,” “believes,” “potential,” “continue,”
“anticipates,” “estimates,” “expects,” “plans,” “intends,”
“targeting,” “confidence,” “may,” “could,” “might,”
“likely,” “will,” “should” or other words that convey uncertainty
of the future events or outcomes to identify these forward-looking statements.
Our forward-looking statements are based on current beliefs and expectations
of our management team that involve risks, potential changes in circumstances,
assumptions, and uncertainties. Any or all of the forward-looking statements
may turn out to be wrong or be affected by inaccurate assumptions we might
make or by known or unknown risks and uncertainties. These forward looking
statements are subject to risks and uncertainties including risks related to
the success and timing of our clinical trials or other studies, risks
associated with the coronavirus pandemic and the other risks set forth in our
filings with the U.S. Securities and Exchange Commission. For all these
reasons, actual results and developments could be materially different from
those expressed in or implied by our forward-looking statements. You are
cautioned not to place undue reliance on these forward-looking statements,
which are made only as of the date of this press release. We undertake no
obligation to publicly update such forward-looking statements to reflect
subsequent events or circumstances.

Source: Aprea Therapeutics, Inc.

Corporate Contacts:

Scott M. Coiante
Sr. Vice President and Chief Financial Officer
617-463-9385

Gregory A. Korbel
Vice President of Business Development
617-463-9385

(https://www.globenewswire.com/NewsRoom/AttachmentNg/4b5be207-2832-49b4-9e6a-15869e433e16)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.